BMS’ Opdivo regimen shows promise in colorectal cancer clinical trials
BMS’ Opdivo plus Yervoy significantly improved progression-free survival in patients with MSI-H/dMMR metastatic colorectal cancer. Credit: Bristol-Myers Squibb Company. bristol myers squib (BMS) is a Phase III CheckMate-8HW clinical trial combining Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment option for microsatellite-high instability (MSI-H) or mismatch repair deficiency (dMMR). reported promising data. Metastatic colorectal […]
BMS completes Phase 3 trial of nivolumab and leratorimab for colorectal cancer
Colorectal cancer: © Peterschreiber.media – Stock.adobe.com Bristol-Myers Squibb is conducting a Phase 3 RELATIVITY study investigating nivolumab (Opdivo) and relatlimab (Opdualag) in patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer (CRC). -123 study (NCT05328908) has been completed and will not progress beyond 1. It is more effective than 4-line treatment because it is […]
BMS Demonstrates Rationale for Opdivo and Yervoy Combination Therapy in First-Line Colorectal Cancer
Photo: California BMS Building Exterior/iStock, hapa bapa Bristol-Myers Squibb on Thursday announced data from the Phase 3 CheckMate-8HW study demonstrating first-line potential for Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy in metastatic colorectal cancer. . BMS did not provide specific data in Thursday’s announcement, but the company said the combination therapy showed “statistically significant results” […]